Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSI June 2026 Index Rebalance: Post-Announcement Positioning

HSI Index Rebalance: March 2026 Post-Event Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>Hang Seng Index's June 2026 rebalance will take place on 8 June. Three ADD names will enter the implementation phase.</li>
<li>Chalco and BeOne reversed their announcement-day gains through the bridge; J&amp;T Express kept a positive bridge return.</li>
<li>Historical ADDs with negative bridge returns had weaker first-week outcomes, while positive-bridge ADDs had mixed first-week outcomes.</li>
</ul>


Hang Seng Index's June 2026 rebalance will take place on 8 June. Three ADD names will enter the implementation phase.
Chalco and BeOne reversed their announcement-day gains through the bridge; J&amp;T Express kept a positive bridge return.
Historical ADDs with negative bridge returns had weaker first-week outcomes, while positive-bridge ADDs had mixed first-week outcomes.


HSI June 2026 Index Rebalance: Pre-Implementation Update

BeOne Medicines

HSI June 2026 Index Rebalance: Pre-Implementation Update